AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 151 min read$CLLS

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Cellectis (NASDAQ:CL

Analysts downgraded several stocks: HSBC cut Banco Santander Brasil (BSBR) to Hold with a $6.2 target; Rosenblatt downgraded Ribbon Communications (RBBN) to Neutral with a $2.2 target; Citizens downgraded Cellectis (CLLS) to Market Perform; Barclays downgraded Scholar Rock (SRRK) to Equal-Weight with a $58 target; Raymond James downgraded Ascendis Pharma (ASND) to Outperform with a $287 target.

Original reporting
benzinga.com
Published Sep 15, 2026, 2:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 5:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CLLS
Bearish
medium confidence
Mentioned
$CLLS · $BSBR · $RBBN · $SRRK · $ASND
Relevance
6/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$CLLSBearishMed
01

Why it matters

The downgrades may lead to short-term price pressure on the affected stocks, though the overall market impact is limited.

02

Market read

Downgrades may trigger modest sell-offs in the listed stocks, with limited broader market effect.

03

What to watch

Potential upcoming earnings or sector catalysts could offset downgrade effects.

Relevance 6/10Novelty 6/10Timing: after Monday close

Background

Analyst rating changes are a routine part of market coverage, reflecting updated views on company prospects.

Company-level read

Ticker impact

$CLLSBearishMedium confidence
Context

Cellectis (NASDAQ:CLLS) was downgraded from Market Outperform to Market Perform.

Expected impact

Potential short-term decline

Evidence & confidence

Downgrade signals weaker outlook, likely prompting sell pressure.

$BSBRNeutralMedium confidence
Context

Banco Santander Brasil (NYSE:BSBR) was downgraded from Buy to Hold.

Expected impact

Flat to slight down

Evidence & confidence

Hold suggests no further upside, may temper buying.

$RBBNBearishMedium confidence
Context

Ribbon Communications (NASDAQ:RBBN) was downgraded from Buy to Neutral.

Expected impact

Possible modest decline

Evidence & confidence

Neutral stance often leads to reduced demand.

$SRRKNeutralMedium confidence
Context

Scholar Rock Holding (NASDAQ:SRRK) was downgraded from Overweight to Equal-Weight.

Expected impact

Flat to slight down

Evidence & confidence

Equal-Weight is a neutral stance, limiting upside.

$ASNDNeutralMedium confidence
Context

Ascendis Pharma (NASDAQ:ASND) was downgraded from Strong Buy to Outperform.

Expected impact

Flat to modest decline

Evidence & confidence

Reduced rating may temper enthusiasm.

Market effects

Sector

Analyst downgrades across diverse sectors may signal broader caution.

Regional

Primarily U.S. listed equities; limited regional effect.

Global

Low global impact beyond individual stocks.

Counterpoint

What could challenge this read

Some investors may view the downgrades as overreaction and look for buying opportunities.

Key entities

  • company
    Cellectis SA

    Biotech firm focused on gene editing.

  • company
    Banco Santander Brasil

    Brazilian banking subsidiary of Santander.

  • company
    Ribbon Communications

    Provider of communications software.

  • company
    Scholar Rock Holding Corp

    Life sciences contract research organization.

  • company
    Ascendis Pharma

    Biopharmaceutical company.

Read at source← All news

Related articles

OCT 27
$RBBNHigh

Ribbon (RBBN) Q3 2026 Earnings Call Transcript

Ribbon (RBBN) reported Q3 2026 revenue up 14% sequentially to $219M, with adjusted EBITDA more than doubling to $27M. IP optical sales grew 17% sequentially, driven by strong US demand and new tier-2 service provider customers. Cloud and edge segment sales increased 11% quarter-over-quarter. Verizon, a top customer, saw sales grow 50% compared to the first half.

finance.yahoo.com2 min
OCT 27
$RBBNMed

Ribbon Communications Q3 Earnings Call Highlights

Ribbon Communications (RBBN) reported Q3 2026 earnings, with Cloud and Edge revenue at $123M, up 11% QoQ. Verizon contributed significantly, with sales up 50% compared to the first half. The company expects Q4 revenue of $233M-$247M and adjusted EBITDA of $40M-$47M. Ribbon anticipates supply constraints and potential demand shifts into Q1 2027.

finance.yahoo.com2 min
OCT 27
$RBBNMedAI 8/10

Ribbon Q3 2026 slides: sequential recovery drives profit beat

Ribbon Communications (RBBN) reported Q3 2026 earnings of $0.07 per share, beating estimates, despite revenue of $219M falling slightly short. Shares rose 4.48% to $1.40. The company highlighted growth in data center interconnect, government/defense, and AI solutions. Revenue increased sequentially, with strong demand in U.S. service provider voice modernization and IP optical solutions.

investing.com2 min
OCT 27
$RBBNMed

Ribbon Communications Inc. Reports Third Quarter 2026 Financial Results

Ribbon Communications Inc. (RBBN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ribbon Communications Inc. Reports Third Quarter 2026 Financial Results Revenue increased 14% sequentially and Net Income improved by $18M; further significant gains expected in 4Q 2026 IP Optical Networks Revenue increased 17% QoQ led by new wins in North America Cl

SEC EDGAR 8-K2 min